{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Rakshit S"],"funding":["NIAID NIH HHS"],"pagination":["985938"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9577398"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["13"],"pubmed_abstract":["This proof-of-concept study tested if prior BCG revaccination can qualitatively and quantitively enhance antibody and T-cell responses induced by Oxford/AstraZeneca ChAdOx1nCoV-19 or COVISHIELD™, an efficacious and the most widely distributed vaccine in India. We compared COVISHIELD™ induced longitudinal immune responses in 21 BCG re-vaccinees (BCG-RV) and 13 BCG-non-revaccinees (BCG-NRV), all of whom were BCG vaccinated at birth; latent tuberculosis negative and SARS-CoV-2 seronegative prior to COVISHIELD™ vaccination. Compared to BCG-NRV, BCG-RV displayed significantly higher and persistent spike-specific neutralizing (n) Ab titers and polyfunctional CD4+ and CD8+ T-cells for eight months post COVISHIELD™ booster, including distinct CD4+IFN-γ+ and CD4+IFN-γ- effector memory (EM) subsets "],"journal":["Frontiers in immunology"],"pubmed_title":["Evidence for the heterologous benefits of prior BCG vaccination on COVISHIELD™ vaccine-induced immune responses in SARS-CoV-2 seronegative young Indian adults."],"pmcid":["PMC9577398"],"funding_grant_id":["UM1 AI068618"],"pubmed_authors":["Maguire TJA","Ottenhoff THM","Rao S","Adiga V","Shivalingaiah S","Parthiban C","Rakshit S","Joosten SA","Ahmed A","McElrath MJ","Netea MG","Geckin B","Chetan Kumar N","Dasgupta P","Vyakarnam A","van Meijgaarden KE","Babji S","D'Souza G","Li Y","Doores KJ","De Rosa SC","Dwarkanath P","Stuart KD","Dias M","Zoodsma M"],"additional_accession":[]},"is_claimable":false,"name":"Evidence for the heterologous benefits of prior BCG vaccination on COVISHIELD™ vaccine-induced immune responses in SARS-CoV-2 seronegative young Indian adults.","description":"This proof-of-concept study tested if prior BCG revaccination can qualitatively and quantitively enhance antibody and T-cell responses induced by Oxford/AstraZeneca ChAdOx1nCoV-19 or COVISHIELD™, an efficacious and the most widely distributed vaccine in India. We compared COVISHIELD™ induced longitudinal immune responses in 21 BCG re-vaccinees (BCG-RV) and 13 BCG-non-revaccinees (BCG-NRV), all of whom were BCG vaccinated at birth; latent tuberculosis negative and SARS-CoV-2 seronegative prior to COVISHIELD™ vaccination. Compared to BCG-NRV, BCG-RV displayed significantly higher and persistent spike-specific neutralizing (n) Ab titers and polyfunctional CD4+ and CD8+ T-cells for eight months post COVISHIELD™ booster, including distinct CD4+IFN-γ+ and CD4+IFN-γ- effector memory (EM) subsets ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2026-05-08T03:10:24.496Z","creation":"2025-02-19T03:23:00.591Z"},"accession":"S-EPMC9577398","cross_references":{"pubmed":["36268023"],"doi":["10.3389/fimmu.2022.985938"]}}